Screener
Syndax Pharmaceuticals SNDX Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $10,843 | $16,580 |
| Accrued expenses and other current liabilities | 74,843 | 103,064 |
| Current portion of right-of-use liability | 487 | 470 |
| Current portion of capital lease | 1 | 2 |
| Total current liabilities | 86,174 | 120,116 |
| Long-term liabilities: | ||
| Royalty interest financing liability, less current portion | 343,965 | 343,909 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's operating lease liabilities (current)?
- Syndax Pharmaceuticals (SNDX) reported operating lease liabilities (current) of $487K in Q1 2026.
- How has Syndax Pharmaceuticals's operating lease liabilities (current) changed year-over-year?
- Syndax Pharmaceuticals's operating lease liabilities (current) increased by 29.2% year-over-year, from $377K to $487K.
- What is the long-term trend for Syndax Pharmaceuticals's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's operating lease liabilities (current) has grown at a 8.3% compound annual growth rate (CAGR), from $316K to $470K.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about Syndax Pharmaceuticals's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude